white → red2 → orange2
Not yet reviewed — this article is pending editorial review by Lyrea.
Citation noticeOur citation system is being overhauled
References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.
25e-NBOMe
25E-NBOMe is a synthetic psychedelic of the substituted phenethylamine class, derived from 2C-E through N-benzylation. It is a potent 5-HT2A receptor agonist that produces effects similar to related compounds such as 25I-NBOMe and 25C-NBOMe. Typically distributed on blotters, it has been sold as a research chemical and is sometimes misrepresented as LSD. Notable risks include significant vasoconstriction and heavy body load, with high doses posing potentially life-threatening cardiovascular effects.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~50 µg
Light50-200 µg
Moderate200-400 µg
Strong400-800 µg
Heavy800+ µg
This substance is typically taken by holding blotter paper or liquid solution beneath the tongue for absorption through the oral mucosa. Compounds in the NBOMe class are known for significant variation in individual response, making it advisable to begin with doses at the lower end of reported ranges.
Duration
Onset15-60 minutes
After Effects2-10 hours
Total5-10 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
25E-NBOMe produces a strongly visual and stimulating psychedelic state typical of the NBOMe series, marked by euphoria, heightened empathy, and a broad alteration of perception. The headspace pairs insight and a softening of the ego with mental stimulation, though confusion can arise as intensity increases. The body load is distinctly stimulating rather than relaxing, with restlessness, muscle tension, and difficulty sleeping persisting through the experience.
Physical
The body load is stimulating and somewhat tense, with restlessness, muscle tension, sweating and chills, appetite loss, and pronounced wakefulness that can make sleep difficult until the effects subside.
Stimulation
The physical character of the experience is energetic and restless rather than relaxing.
Uncomfortable
Cognitive
The mental state combines euphoria, empathy, and introspective insight with a generally stimulated thought stream. Ego boundaries soften at higher intensities, and confusion is possible.
Emotional
Visual
Visual effects are a central component of the experience, appearing with both open and closed eyes and featuring markedly brightened color.
Tactile
Tactile sensation is enhanced, with touch feeling more pronounced and engaging.
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
25E-NBOMe acts as an agonist at serotonin 5-HT2 receptors. In rodent models, the compound produces the head-twitch response, a behavioral proxy for psychedelic activity. 25E-NBOMe has also demonstrated reinforcing effects in rodents, including conditioned place preference and self-administration, which were mediated by increased dopaminergic signaling in the nucleus accumbens. Blockade of the dopamine D1 receptor was found to attenuate the conditioned place preference induced by the substance.
Pharmacokinetics
Absorption & half-lifenot documented yetMetabolitesnone documented yet
Interactions
Interactions not written up yet
An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.
Tolerance
Tolerance not written up yet
Harm Potential
Addiction & Dependence
Psychological
Rodent studies have demonstrated reinforcing effects including conditioned place preference and self-administration, mediated by increased dopaminergic signaling in the nucleus accumbens. Blockade of the dopamine D1 receptor attenuated these reinforcing effects.
Toxicity
Cardiovascular
Vasoconstriction is a noted effect that at high doses can potentially endanger life; users should exercise particular caution with dosing.
History & Culture
25E-NBOMe first appeared in scientific literature around 2012, emerging as part of the broader NBOMe series of substituted phenethylamines. This class of compounds, which includes related substances such as 25I-NBOMe and 25C-NBOMe, gained attention during this period as novel psychoactive substances. Following its initial scientific documentation, 25E-NBOMe subsequently appeared on the recreational drug market alongside other members of this chemical family.
Legality
By Country
Illegal2
SwedenIllegal25E-NBOMe is prohibited in Sweden and is listed by exact name in Förteckning I, which covers substances that normally have no medical use. The classification took effect on 18 January 2019 and remains in the current official consolidation through HSLF-FS 2026:26. Unauthorized possession, use, transfer, acquisition for transfer, procurement, processing, packaging, transport, storage, and facilitation of narcotics trade are criminal offences; manufacture is covered when intended for abuse, while procurement and the listed handling offences concern narcotics not intended for personal use, and import/export offences are governed separately by smuggling law. Import, export, manufacture, offering for sale, transfer, and possession are permitted only for specified medical, scientific, particularly urgent public-benefit, or specifically authorized industrial purposes.
United KingdomIllegal (analog/blanket ban)25E-NBOMe is treated as a Class A controlled drug in the United Kingdom under the generic structural definition in Schedule 2, Part I, paragraph 1(f) of the Misuse of Drugs Act 1971. The provision has covered NBOMe compounds since 10 June 2014 and restricts possession, possession with intent to supply, production, supply, offering to supply, import and export, subject to statutory exceptions. On indictment, possession carries a maximum of seven years' imprisonment, while production, supply and possession with intent to supply carry a maximum of life imprisonment; a fine may also be imposed.
References
Citations
- Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika (konsoliderad t.o.m. HSLF-FS 2026:26). lakemedelsverket.se (n.d.). https://www.lakemedelsverket.se/globalassets/dokument/lagar-och-regler/lvfs/lvfs-2011-10-konsoliderad.pdf1
- HSLF-FS 2019:1, föreskrifter om ändring i LVFS 2011:10 om förteckningar över narkotika. lakemedelsverket.se (n.d.). https://www.lakemedelsverket.se/globalassets/dokument/lagar-och-regler/hslf-fs/hslf-fs-2019-1.pdf1
- Förordning (1992:1554) om kontroll av narkotika. riksdagen.se (n.d.). https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/forordning-19921554-om-kontroll-av-narkotika_sfs-1992-1554/1
- SFS 2018:2057, förordning om ändring i förordningen (1992:1554) om kontroll av narkotika. svenskforfattningssamling.se (n.d.). https://svenskforfattningssamling.se/sites/default/files/sfs/2018-12/SFS2018-2057.pdf1
- Lag (1992:860) om kontroll av narkotika. riksdagen.se (n.d.). https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/lag-1992860-om-kontroll-av-narkotika_sfs-1992-860/1
- Narkotikastrafflag (1968:64). riksdagen.se (n.d.). https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/narkotikastrafflag-196864_sfs-1968-64/1
- Misuse of Drugs Act 1971, Schedule 2 — Controlled Drugs. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/schedule/21
- The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/uksi/2014/1106/made1
- PubChem PUG REST synonyms for CID 118796522. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/118796522/synonyms/JSON1
- PubChem PUG REST compound properties for CID 118796522. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/118796522/property/IUPACName,Title,MolecularFormula,CanonicalSMILES/JSON1
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass reviewPending
Not yet reviewed — this article is pending editorial review by Lyrea.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 25e-NBOMe article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.